WO1993009221A1 - Targeted delivery of virus vector to mammalian cells - Google Patents
Targeted delivery of virus vector to mammalian cells Download PDFInfo
- Publication number
- WO1993009221A1 WO1993009221A1 PCT/SE1992/000745 SE9200745W WO9309221A1 WO 1993009221 A1 WO1993009221 A1 WO 1993009221A1 SE 9200745 W SE9200745 W SE 9200745W WO 9309221 A1 WO9309221 A1 WO 9309221A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- virus
- antibody
- complex according
- cell
- antigen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
Definitions
- the present invention relates to a complex between virus the cell binding receptor of which has been inacti vated and an antibody.
- the invention is applicable to si tuations where it is desireable to introduce viruses int selected mammalian cells for medicinal purposes.
- the specificity of the virus receptor is analogous to the specificity of antibodies against certain tumor antigens, in that the influenza virus hemagglutinin binds to NeuAc2-3Gal-R, which is pre ⁇ sent on the same structures as many human tumor associat antigens.
- the main object of the present invention is to pro ⁇ vide techniques enabling introduction of viruses into mam malian cells for providing desired biological action in such cells.
- Another object of the invention is to enable virus vectors or infectious viruses to be directed to specific cells in a living animal body.
- Yet another purpose is to provide techniques making it possible for viruses to selectively enter specific cells in a living animal body.
- the invention provides for a complex between a virus and an antigen-binding substance selected from antibodies, fragments of anti ⁇ bodies and antigen-binding peptides, the cell binding receptor of said virus being inactivated.
- Said substance has the ability to interact with a specific antigen on the surface of a mammalian cell which antigen is different from the cellular structure which would otherwise mediate binding of the virus to the cell surface.
- said substance has the ability to mediate entrance of a virus vector or infectious virus into the cell.
- the substance can either be a monoclonal antibody or a fragment of a whole antibody.
- the substance can be bound to the virus in different ways, such as by chemical conjugation, by bridging the substance to the virus by an immunochemical reagent, or by using a bifunctional substance binding to the virus as well as to a cellular antigen.
- the substance may also be expressed on the virus sur ⁇ face envelope following cloning into the virus genome of gene(s) for whole antibodies or fragments thereof.
- the inactivation of the viral cell receptor in accor ⁇ dance with the present invention can take place by chemi ⁇ cal means, by a specific antibody or by gene technological manipulation of the viral genome.
- the gene for the viral cell receptor or parts thereof can be replaced with antibody genes ,
- the complex according to the present invention is in ⁇ tended for medicinal use.
- the complex can be used as a vector to introduce genes into cells or organs for spe ⁇ cific therapeutical purposes.
- the complex may also be used to express viral antigens on the cell surface for such purposes or it can be used to cause an infection in cells carrying the substance against which the antibody is reac ⁇ tive.
- virus By using an antibody which binds to a cellular mem ⁇ brane antigen which can be internalized into the cell, virus can bind to the cell via an antibody-antigen reac ⁇ tion and then penetrate into the cell and replicate caus ⁇ ing a viral infection. Furthermore, since antigens are known which are more or less unique for certain types of cells, virus can be selectively directed to enter and in- feet specific cells in the body. Examples of such antige are some cell-differentiation antigens, such as CD19 on B cells, and certain tumor-associated antigens on carcinoma cells.
- the invention will therefore make it possible to di ⁇ rect virus vectors or infectious viruses to specific cell in the body with the possibility of introducing functiona genes into selected cells or organs in vivo or to cause a viral infection in certain cells.
- the following table shows examples of viral receptor and their cellular ligands. Receptors such as these are possible candidates for use within the present invention.
- retroviruses When virus replicates in the cell certain viral pro ⁇ teins are degraded to peptides. These peptides are bound to so called MHC antigens within the cell and are there ⁇ after transported to the cell membrane where the peptide- MHC complex serve as target for a very important defense system, i.e. virus specific cytotoxic T cells, which actu ally kill the virus infected cell.
- virus e.g. retroviruses
- retroviruses are integrated into the host cell genome in the form of provirus which may thereafter be replicated.
- retroviruses can be mani ⁇ pulated so that they no longer replicate but can be used as vectors to introduce new genes into mammalian cells * .
- the use of retroviral vectors offers a practical means for gene therapy in humans. However, at the present time the use of retroviral vectors are largely restricted to cells of hemopoietic origin.
- the viral receptor can be blocked with an antibody which may in turn be conjugated with an antibody of the desired specificity.
- the viral receptor can be inactivated by chemical- or gene technological methods and the replacing antibody can then be chemically coupled directly to the virus par ⁇ ticle.
- the gene for the viral receptor can be replaced with the genes for the replacing antibody.
- Another area is immunotherapy of tumor diseases where the invention migt be used for gene therapy or to intro ⁇ quiz virus into tumor cells with the intent of expressing viral antigens at the cell surface converting the cells into possible targets for the virus-specific cytotoxic T cells.
- the invention will be further illustrated in the fo lowing by specific examples which are not construed to r strict the scope of the invention otherwise than defined by the appended claims.
- the following examples demonstrate that the binding specificity of a virus can be blocked and replaced with that of an antibody.
- the binding and in ⁇ fection of Influenza virus A/PR/8 to human colon carcino cells Colo 205 is used.
- the cell binding of influenza vi rus is depending on a specific binding molecule, Hemaggl tinin (HA), which is present in the viral envelope, and which binds to NeuAc2-3Gal-R, present on many mammalian cells.
- HA Hemaggl tinin
- the cell lin producing the OKT9 antibody is obtainable from the Ameri ⁇ can Type Culture Collection.
- Influenza A/PR/8 was obtained from Statens Bakterio- logiska Laboratorium, S-10521 Sweden, Sweden.
- Hybridoma cells were obtained from the American Type Culture Collection, 12301 Parklawn Drive, Rockville, Mary ⁇ land 20852, USA. Hybridoma cells were grown in Iscove's medium supplemented with 10% fetal calf serum. Antibody production was performed in dialysis tubings (Sj ⁇ gren- Jansson E and Jeansson S: Large-scale Production of Mono ⁇ clonal Antibodies in Dialysis Tubin, J.Immunol.Meth., Vol 84, pp 359-364, 1985) and antibodies were purified by af ⁇ finity chromatography on a Protein A Sepharose CL-4B (Pharmacia, Uppsala, Sweden)(Ey PL, Prowse SJ and Jenkin CR: Isolation of pure IgGl, IgG 2 and Ig ?h immunoglobu- lins from mouse serum using Protein A-Sepharose. Immuno- chemistry Vol 15, pp 429-436, 1978).
- Antibody conjugates were prepared using the hetero- bifunctional reagent N-succinimidyl (2 pyridyldithio)- propionate, SPDP (Pharmacia, Uppsala, Sweden) (Carlsson J, Drevin H and Axen R: Protein thiolation and reversible protein protein conjugation. N-succinimidyl 3(2 pyridyldi ⁇ thio)propionate - a new heterobifunctional reagent. Biochem.J., Vol 173, pp 723-737, 1978). Conjugates were purified from unreacted antibody by gel filtration on Superdex 200 (Pharmacia, Uppsala, Sweden). Titration of virus by Hemagglutination:
- Hemagglutination of human blood group 0 red blood cells was performed in 96-well trays using standard me ⁇ thods (Mahy BWJ, ed: Virology, a practical approach. IRL Press, Oxford, 1985).
- Colo 205 colon carcinoma cells were obtained from t American Type Culture Collection, 12301 Parklawn Drive, Rockville, Maryland 20852, USA, and maintained in Iscove' medium with 10% fetal calf serum.
- Inhibition of viral binding to its cellular ligand was measured by the hemagglutination method.
- Virus 800 HAU (HemAgglutinating Units)/ml, was incubated for lh at room temperature with antibody at different concentratio and then allowed to agglutinate human red blood cells.
- H PEG-1 antibody caused complete inhibition of agglutinati at 7 ⁇ g/ml or more wheras the corresponding figure for HK- PEG-1 conjugated to 0KT9 was 10 ⁇ g/ml.
- HK-PEG-1 conjugates to mediate viral infection
- HK-PEG-1 or HK-PEG-1 conjugated to 0KT9 was incubate with 100 HAU of A/PR/8 virus for 1 hour at room tempera ⁇ ture in order to block the HA molecules in the viral en ⁇ velope. Thereafter the virus preparations were incubated . together with 2x10 Colo 205 cells in 1 ml PBS for 1 hour at 37°. The cells were washed three times with PBS by c n tr.ifugation, suspended in 1 ml of complete medium and in ⁇ cubated at 37° for 24 hours. Presence of virus in the me ⁇ dium was assessed by hemagglutination. The results are shown in Table 2 below.
- Colo 205 cells infected with Influenza A/PR/8 pretreated with different antibodies were treated with different antibodies.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Plant Pathology (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP5508351A JPH07502026A (en) | 1991-10-30 | 1992-10-28 | virus antibody complex |
CA002122613A CA2122613C (en) | 1991-10-30 | 1992-10-28 | Targeted delivery of virus vector to mammalian cells |
AT92922980T ATE224442T1 (en) | 1991-10-30 | 1992-10-28 | TARGETED INTRODUCTION OF A VIRUS VECTOR INTO MAMMAL CELLS. |
US08/232,028 US5695991A (en) | 1991-10-30 | 1992-10-28 | Targeted delivery of virus vector to mammalian cells |
EP92922980A EP0614486B1 (en) | 1991-10-30 | 1992-10-28 | Targeted delivery of virus vector to mammalian cells |
DE69232782T DE69232782T2 (en) | 1991-10-30 | 1992-10-28 | Targeted introduction of a virus vector into mammalian cells. |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9103183-1 | 1991-10-30 | ||
SE9103183A SE503225C2 (en) | 1991-10-30 | 1991-10-30 | Virus-antibody complex for introduction of virus into mammalian cells |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1993009221A1 true WO1993009221A1 (en) | 1993-05-13 |
Family
ID=20384166
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/SE1992/000745 WO1993009221A1 (en) | 1991-10-30 | 1992-10-28 | Targeted delivery of virus vector to mammalian cells |
Country Status (9)
Country | Link |
---|---|
US (1) | US5695991A (en) |
EP (1) | EP0614486B1 (en) |
JP (1) | JPH07502026A (en) |
AT (1) | ATE224442T1 (en) |
CA (1) | CA2122613C (en) |
DE (1) | DE69232782T2 (en) |
ES (1) | ES2180538T3 (en) |
SE (1) | SE503225C2 (en) |
WO (1) | WO1993009221A1 (en) |
Cited By (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994010323A1 (en) * | 1992-11-04 | 1994-05-11 | Imperial Cancer Research Technology Limited | Virus with modified binding moiety specific for the target cells |
WO1994024299A1 (en) * | 1993-04-08 | 1994-10-27 | Boehringer Ingelheim International Gmbh | Adenovirus for the transfer of foreign dna into higher eucaryotic cells |
WO1997005266A1 (en) * | 1995-07-25 | 1997-02-13 | Introgene B.V. | Methods and means for targeted gene delivery |
WO1997038723A1 (en) * | 1996-04-16 | 1997-10-23 | Immusol Incorporated | Targeted viral vectors |
US5695991A (en) * | 1991-10-30 | 1997-12-09 | Got-A-Gene Ab | Targeted delivery of virus vector to mammalian cells |
US5753499A (en) * | 1994-12-23 | 1998-05-19 | New York University | Viral vector complexes having adapters of predefined valence |
EP0846772A1 (en) * | 1996-11-29 | 1998-06-10 | Hoechst Aktiengesellschaft | Multifunctional ligand system for cell-specific transfer of nucleic acid |
EP0870839A1 (en) * | 1995-11-13 | 1998-10-14 | Takara Shuzo Co. Ltd. | Method for gene introduction into target cells by retrovirus |
WO1998047916A1 (en) * | 1997-04-18 | 1998-10-29 | President And Fellows Of Harvard College | Bifunctional polypeptides for cell-specific viral targeting |
WO1999040214A2 (en) * | 1998-02-09 | 1999-08-12 | Genzyme Corporation | Nucleic acid delivery vehicles |
US6004798A (en) * | 1997-05-14 | 1999-12-21 | University Of Southern California | Retroviral envelopes having modified hypervariable polyproline regions |
US6060316A (en) * | 1998-06-09 | 2000-05-09 | President And Fellows Of Harvard College | Methods of targeting of viral entry |
US6287857B1 (en) | 1998-02-09 | 2001-09-11 | Genzyme Corporation | Nucleic acid delivery vehicles |
US6358524B1 (en) | 1996-02-13 | 2002-03-19 | Aventis Pharma Deutschland Gmbh | Target cell-specific non-viral vectors for inserting genes into cells, pharmaceutical compositions comprising such vectors and their use |
US6432699B1 (en) | 1997-03-28 | 2002-08-13 | New York University | Viral vectors having chimeric envelope proteins containing the IgG-binding domain of protein A |
US6864082B2 (en) | 1997-04-10 | 2005-03-08 | University Of Southern California | Modified viral surface proteins for binding to extracellular matrix components |
US7078483B2 (en) | 1998-04-29 | 2006-07-18 | University Of Southern California | Retroviral vectors including modified envelope escort proteins |
US7361354B1 (en) | 1999-11-25 | 2008-04-22 | Viralytics Limited | Methods for treating malignancies expressing ICAM-1 using coxsackie a group viruses |
US7485292B2 (en) | 2002-12-18 | 2009-02-03 | Viralytics Limited | Method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis |
WO2009127537A1 (en) | 2008-04-17 | 2009-10-22 | GÜNZBURG, Walter | Post release modification of viral envelopes |
WO2018093932A2 (en) | 2016-11-16 | 2018-05-24 | Immunomic Therapeutics, Inc. | Nucleic acids for treatment of allergies |
WO2018195527A1 (en) | 2017-04-22 | 2018-10-25 | Immunomic Therapeutics, Inc. | Improved lamp constructs |
WO2018204534A1 (en) | 2017-05-02 | 2018-11-08 | Immunomic Therapeutics, Inc. | Lamp (lysosomal associated membrane protein) constructs comprising cancer antigens |
WO2019222281A1 (en) | 2018-05-15 | 2019-11-21 | Immunomic Therapeutics, Inc | Improved lamp constructs comprising allergens |
WO2021077051A1 (en) | 2019-10-18 | 2021-04-22 | Immunomic Therapeutics, Inc | Improved lamp constructs comprising cancer antigens |
US11266736B2 (en) | 2008-04-17 | 2022-03-08 | Vin De Bona Trading Company Pte Ltd | Method of painting micro vesicles |
WO2023201201A1 (en) | 2022-04-10 | 2023-10-19 | Immunomic Therapeutics, Inc. | Bicistronic lamp constructs comprising immune response enhancing genes and methods of use thereof |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5846782A (en) | 1995-11-28 | 1998-12-08 | Genvec, Inc. | Targeting adenovirus with use of constrained peptide motifs |
US6465253B1 (en) | 1994-09-08 | 2002-10-15 | Genvec, Inc. | Vectors and methods for gene transfer to cells |
US5770442A (en) | 1995-02-21 | 1998-06-23 | Cornell Research Foundation, Inc. | Chimeric adenoviral fiber protein and methods of using same |
US6127525A (en) * | 1995-02-21 | 2000-10-03 | Cornell Research Foundation, Inc. | Chimeric adenoviral coat protein and methods of using same |
US20060002949A1 (en) | 1996-11-14 | 2006-01-05 | Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. | Transcutaneous immunization without heterologous adjuvant |
US6797276B1 (en) | 1996-11-14 | 2004-09-28 | The United States Of America As Represented By The Secretary Of The Army | Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response |
US20060292121A1 (en) * | 1998-04-29 | 2006-12-28 | Hall Frederick L | Retroviral vectors including modified envelope escort protein |
WO1999055365A1 (en) | 1998-04-30 | 1999-11-04 | Cornell Research Foundation, Inc. | Adenoviral vectors with tandem fiber proteins |
EP1112372A1 (en) | 1998-09-11 | 2001-07-04 | Genvec, Inc. | Alternatively targeted adenovirus |
JP2003534806A (en) * | 2000-05-31 | 2003-11-25 | ジェンベク、インコーポレイティッド | Methods and compositions for targeting adenovirus vectors |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1989007136A2 (en) * | 1988-02-05 | 1989-08-10 | Whitehead Institute For Biomedical Research | Modified hepatocytes and uses therefor |
WO1990012087A1 (en) * | 1989-04-05 | 1990-10-18 | Novacell Corporation | Infectious targetted replication-defective virion |
FR2649119A1 (en) * | 1989-06-30 | 1991-01-04 | Centre Nat Rech Scient | Process for guiding retroviruses using bifunctional complexes |
WO1991002805A2 (en) * | 1989-08-18 | 1991-03-07 | Viagene, Inc. | Recombinant retroviruses delivering vector constructs to target cells |
WO1991004753A1 (en) * | 1989-10-02 | 1991-04-18 | Cetus Corporation | Conjugates of antisense oligonucleotides and therapeutic uses thereof |
WO1992006180A1 (en) * | 1990-10-01 | 1992-04-16 | University Of Connecticut | Targeting viruses and cells for selective internalization by cells |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4364934A (en) * | 1979-12-04 | 1982-12-21 | Ortho Pharmaceutical Corporation | Monoclonal antibody to a human early thymocyte antigen and methods for preparing same |
US5428132A (en) * | 1987-10-11 | 1995-06-27 | United States Of America | Conjugate and method for integration of foreign DNA into cells |
SE503225C2 (en) * | 1991-10-30 | 1996-04-22 | Leif Lindholm Konsult Ab | Virus-antibody complex for introduction of virus into mammalian cells |
-
1991
- 1991-10-30 SE SE9103183A patent/SE503225C2/en not_active IP Right Cessation
-
1992
- 1992-10-28 US US08/232,028 patent/US5695991A/en not_active Expired - Fee Related
- 1992-10-28 DE DE69232782T patent/DE69232782T2/en not_active Revoked
- 1992-10-28 JP JP5508351A patent/JPH07502026A/en not_active Ceased
- 1992-10-28 WO PCT/SE1992/000745 patent/WO1993009221A1/en not_active Application Discontinuation
- 1992-10-28 ES ES92922980T patent/ES2180538T3/en not_active Expired - Lifetime
- 1992-10-28 CA CA002122613A patent/CA2122613C/en not_active Expired - Fee Related
- 1992-10-28 EP EP92922980A patent/EP0614486B1/en not_active Revoked
- 1992-10-28 AT AT92922980T patent/ATE224442T1/en not_active IP Right Cessation
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1989007136A2 (en) * | 1988-02-05 | 1989-08-10 | Whitehead Institute For Biomedical Research | Modified hepatocytes and uses therefor |
WO1990012087A1 (en) * | 1989-04-05 | 1990-10-18 | Novacell Corporation | Infectious targetted replication-defective virion |
FR2649119A1 (en) * | 1989-06-30 | 1991-01-04 | Centre Nat Rech Scient | Process for guiding retroviruses using bifunctional complexes |
WO1991002805A2 (en) * | 1989-08-18 | 1991-03-07 | Viagene, Inc. | Recombinant retroviruses delivering vector constructs to target cells |
WO1991004753A1 (en) * | 1989-10-02 | 1991-04-18 | Cetus Corporation | Conjugates of antisense oligonucleotides and therapeutic uses thereof |
WO1992006180A1 (en) * | 1990-10-01 | 1992-04-16 | University Of Connecticut | Targeting viruses and cells for selective internalization by cells |
Non-Patent Citations (2)
Title |
---|
Proc. Natl. Acad. Sci., Vol. 86, December 1989, PIERRE ROUX et al.: "A versatile and potentially general approach to the targeting of specific cell types by retroviruses: Application to the infection of human cells by means of major histocompatibility complex class I and class II antigens by mouse ecotropic..", * |
Proc. Natl. Acad. Sci., Vol. 87, April 1990, JEAN-PAUL LEONETTI et al.: "Antibody-targeted liposomes containing oligodeoxyribonucleotides complementary to viral RNA selectively inhibit viral replication", see page 2448 - page 2451. * |
Cited By (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5695991A (en) * | 1991-10-30 | 1997-12-09 | Got-A-Gene Ab | Targeted delivery of virus vector to mammalian cells |
GB2286593A (en) * | 1992-11-04 | 1995-08-23 | Imp Cancer Res Tech | Virus with modified binding moiety specific for the target cells |
EP1038967A3 (en) * | 1992-11-04 | 2006-02-01 | Transgene S.A. | Virus with modified binding moiety specific for the target cells |
EP1038967A2 (en) * | 1992-11-04 | 2000-09-27 | Transgene S.A. | Virus with modified binding moiety specific for the target cells |
WO1994010323A1 (en) * | 1992-11-04 | 1994-05-11 | Imperial Cancer Research Technology Limited | Virus with modified binding moiety specific for the target cells |
WO1994024299A1 (en) * | 1993-04-08 | 1994-10-27 | Boehringer Ingelheim International Gmbh | Adenovirus for the transfer of foreign dna into higher eucaryotic cells |
US5753499A (en) * | 1994-12-23 | 1998-05-19 | New York University | Viral vector complexes having adapters of predefined valence |
US7781208B2 (en) | 1995-07-25 | 2010-08-24 | Crucell Holland B.V. | Methods and means for targeted gene delivery |
WO1997005266A1 (en) * | 1995-07-25 | 1997-02-13 | Introgene B.V. | Methods and means for targeted gene delivery |
US6261554B1 (en) | 1995-07-25 | 2001-07-17 | Introgene B.V. | Compositions for targeted gene delivery |
US7033834B2 (en) | 1995-07-25 | 2006-04-25 | Crucell Holland B.V. | Methods and means for targeted gene delivery |
US7446170B2 (en) | 1995-11-13 | 2008-11-04 | Takara Bio Inc. | Method for gene transfer into target cells with retrovirus |
EP0870839A4 (en) * | 1995-11-13 | 2000-01-19 | Takara Shuzo Co | Method for gene introduction into target cells by retrovirus |
US7790849B2 (en) | 1995-11-13 | 2010-09-07 | Takara Bio Inc. | Enhancement of retroviral gene transduction employing polypeptides comprising the fibronectin heparin II binding domain |
EP0870839A1 (en) * | 1995-11-13 | 1998-10-14 | Takara Shuzo Co. Ltd. | Method for gene introduction into target cells by retrovirus |
US6358524B1 (en) | 1996-02-13 | 2002-03-19 | Aventis Pharma Deutschland Gmbh | Target cell-specific non-viral vectors for inserting genes into cells, pharmaceutical compositions comprising such vectors and their use |
WO1997038723A1 (en) * | 1996-04-16 | 1997-10-23 | Immusol Incorporated | Targeted viral vectors |
EP0846772A1 (en) * | 1996-11-29 | 1998-06-10 | Hoechst Aktiengesellschaft | Multifunctional ligand system for cell-specific transfer of nucleic acid |
US6432699B1 (en) | 1997-03-28 | 2002-08-13 | New York University | Viral vectors having chimeric envelope proteins containing the IgG-binding domain of protein A |
US8530441B2 (en) | 1997-04-10 | 2013-09-10 | University Of Southern California | Transgene delivering retrovirus targeting collagen exposed at site of tissue injury |
US6864082B2 (en) | 1997-04-10 | 2005-03-08 | University Of Southern California | Modified viral surface proteins for binding to extracellular matrix components |
US8871734B2 (en) | 1997-04-10 | 2014-10-28 | The University Of Southern California | Transgene delivering retrovirus targeting collagen exposed at site of tissue injury |
US8148509B2 (en) | 1997-04-10 | 2012-04-03 | University Of Southern California | Transgene delivering retrovirus targeting collagen exposed at site of tissue injury |
US7347998B2 (en) | 1997-04-10 | 2008-03-25 | University Of Southern California | Method of delivering therapeutic agents to site of tissue injury |
US7820157B2 (en) | 1997-04-10 | 2010-10-26 | University Of Southern California | Transgene delivering retrovirus targeting collagen exposed at site of tissue injury |
WO1998047916A1 (en) * | 1997-04-18 | 1998-10-29 | President And Fellows Of Harvard College | Bifunctional polypeptides for cell-specific viral targeting |
US6004798A (en) * | 1997-05-14 | 1999-12-21 | University Of Southern California | Retroviral envelopes having modified hypervariable polyproline regions |
US6287857B1 (en) | 1998-02-09 | 2001-09-11 | Genzyme Corporation | Nucleic acid delivery vehicles |
WO1999040214A3 (en) * | 1998-02-09 | 1999-11-11 | Genzyme Corp | Nucleic acid delivery vehicles |
WO1999040214A2 (en) * | 1998-02-09 | 1999-08-12 | Genzyme Corporation | Nucleic acid delivery vehicles |
US7078483B2 (en) | 1998-04-29 | 2006-07-18 | University Of Southern California | Retroviral vectors including modified envelope escort proteins |
US6060316A (en) * | 1998-06-09 | 2000-05-09 | President And Fellows Of Harvard College | Methods of targeting of viral entry |
US7361354B1 (en) | 1999-11-25 | 2008-04-22 | Viralytics Limited | Methods for treating malignancies expressing ICAM-1 using coxsackie a group viruses |
US8722036B2 (en) | 1999-11-25 | 2014-05-13 | Viralytics Limited | Methods for treating malignancies using coxsackieviruses |
US7485292B2 (en) | 2002-12-18 | 2009-02-03 | Viralytics Limited | Method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis |
WO2009127537A1 (en) | 2008-04-17 | 2009-10-22 | GÜNZBURG, Walter | Post release modification of viral envelopes |
US9139817B2 (en) | 2008-04-17 | 2015-09-22 | Vin de Bona Trading Co. Pte Ltd. | Post release modification of viral envelopes |
US9919046B2 (en) | 2008-04-17 | 2018-03-20 | Vin De Bona Trading Co. Pte Ltd | Post release modification of viral envelopes |
US11266736B2 (en) | 2008-04-17 | 2022-03-08 | Vin De Bona Trading Company Pte Ltd | Method of painting micro vesicles |
WO2018093932A2 (en) | 2016-11-16 | 2018-05-24 | Immunomic Therapeutics, Inc. | Nucleic acids for treatment of allergies |
WO2018195527A1 (en) | 2017-04-22 | 2018-10-25 | Immunomic Therapeutics, Inc. | Improved lamp constructs |
WO2018204534A1 (en) | 2017-05-02 | 2018-11-08 | Immunomic Therapeutics, Inc. | Lamp (lysosomal associated membrane protein) constructs comprising cancer antigens |
WO2019222281A1 (en) | 2018-05-15 | 2019-11-21 | Immunomic Therapeutics, Inc | Improved lamp constructs comprising allergens |
WO2021077051A1 (en) | 2019-10-18 | 2021-04-22 | Immunomic Therapeutics, Inc | Improved lamp constructs comprising cancer antigens |
WO2023201201A1 (en) | 2022-04-10 | 2023-10-19 | Immunomic Therapeutics, Inc. | Bicistronic lamp constructs comprising immune response enhancing genes and methods of use thereof |
Also Published As
Publication number | Publication date |
---|---|
EP0614486A1 (en) | 1994-09-14 |
ATE224442T1 (en) | 2002-10-15 |
JPH07502026A (en) | 1995-03-02 |
EP0614486B1 (en) | 2002-09-18 |
CA2122613C (en) | 2003-08-19 |
DE69232782D1 (en) | 2002-10-24 |
ES2180538T3 (en) | 2003-02-16 |
SE9103183D0 (en) | 1991-10-30 |
SE503225C2 (en) | 1996-04-22 |
CA2122613A1 (en) | 1993-05-13 |
DE69232782T2 (en) | 2003-02-20 |
SE9103183L (en) | 1993-05-01 |
US5695991A (en) | 1997-12-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5695991A (en) | Targeted delivery of virus vector to mammalian cells | |
AU671084B2 (en) | Composition for inserting nucleic acid complexes into higher eucaryotic cells | |
Burton | A vaccine for HIV type 1: the antibody perspective | |
JP4482054B2 (en) | Vectors derived from antibodies for intracellular transport of substances | |
JP3583420B2 (en) | Targeted immunization with bispecific reagents | |
US20030175973A1 (en) | Targeted recombinant viral vectors | |
JP4716350B2 (en) | Antibodies against latency membrane proteins and their use | |
US5981273A (en) | Composition comprising an endosomolytic agent for introducing nucleic acid complexes into higher eucaryotic cells | |
Pillemer et al. | Transformation-associated proteins in murine B-cell lymphomas that are distinct from Abelson virus gene products. | |
CN108640992A (en) | Anti-human PD1 antibody and its application | |
EP1491210B1 (en) | Therapeutic drug using antibody-presenting hollow protein nanoparticles and hollow protein nanoparticles | |
JP2000506361A (en) | Immunovectors for intracellular and nuclear transport | |
WO1998034956A1 (en) | Non-covalent complex comprising at least an antibody and element binding with immunoglobulins associated with an active substance, method of preparing and applications | |
KR100241685B1 (en) | Composition for inserting nucleic acid complexes into higher eukaryotic cells | |
RU2217162C2 (en) | Vaccine against viral infections | |
JPH06506947A (en) | Antivirus hybrid antibody | |
CN116253794A (en) | Antibody for CAR-T cell regulation and control and application thereof | |
Risinskaya et al. | Transfection of the Newcastle disease virus hemagglutinin-neuraminidase gene into murine myeloma cells for induction of host-versus-tumor immune response. | |
Roux et al. | Cell Targeting by Recombinant Retroviruses Using Bi-Specific Antibody Complexes | |
CN118126954A (en) | CAR-T cell and application thereof in preparation of AIDS immunotherapy drugs | |
CN115873130A (en) | CAR molecule targeting SIA-IgG, CAR-T cell and application | |
CS276448B6 (en) | Process for preparing permanent fused cells | |
Bordería et al. | Towards a genetic AIDS vaccine | |
Valladares | Forms of the cancerigenic principle, cell clones, and Koch’s postulates | |
KR960031610A (en) | Tobacco Plants Producing Assembled Antibodies Against Hepatitis B Virus |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2122613 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1992922980 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 08232028 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1992922980 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1992922980 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1992922980 Country of ref document: EP |